NEW YORK, April 16, 2024 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (ITCI) (“Intra-Cellular Therapies”), a biopharmaceutical company focused on the development and commercialization of ...
Johnson & Johnson is starting the year off strong with a $14.6 billion acquisition of the biopharma firm Intra-Cellular Therapies — best known for its blockbuster drug Caplyta. The deal was announced ...
In the preceding three months, 6 analysts have released ratings for Intra-Cellular Therapies (NASDAQ:ITCI), presenting a wide array of perspectives from bullish to bearish. The table below provides a ...
11monon MSN
Intra-Cellular Therapies (ITCI): Among the Best Biotech Stocks to Buy According to Billionaires
We recently compiled a list of the 15 Best Biotech Stocks to Buy According to Billionaires. In this article, we are going to ...
Shares of Intra-Cellular Therapies Inc. (NASDAQ:ITCI) are trading higher Monday after Johnson & Johnson agreed to acquire the company. What To Know: Johnson & Johnson on Monday entered into a ...
We recently compiled a list of the These 10 Firms Dominated Last Week’s Rally. In this article, we are going to take a look at where Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) stands against the ...
We recently compiled a list of the Why These 15 Stocks Are Skyrocketing in 2025. In this article, we are going to take a look at where Intra-Cellular Therapies (NASDAQ:ITCI) stands against the other ...
NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating whether the sale of Intra-Cellular Therapies, Inc. (NASDAQ: ITCI) to Johnson & Johnson for $132.00 per share ...
Aaron McDade is a breaking news reporter for Investopedia. He is an experienced journalist who has covered everything from the latest in business and tech news to sports and international news like ...
NEW YORK, April 17, 2024 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies (ITCI), Inc. (“Intra-Cellular Therapies”), a biopharmaceutical company focused on the development and commercialization of ...
Intra-Cellular Therapies (NASDAQ:ITCI) underwent analysis by 6 analysts in the last quarter, revealing a spectrum of viewpoints from bullish to bearish. The following table summarizes their recent ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results